Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T22:50:28.506Z Has data issue: false hasContentIssue false

Rising Kratom Use and Toxicity: An Observational Study, 2015-2024

Published online by Cambridge University Press:  31 July 2026

E. B. Towers*
Affiliation:
Medical Scientist Training Program, University of Virginia, Charlottesville
Y. T. Thomas
Affiliation:
Henry J.N. Taub Department of Emergency Medicine, Baylor College of Medicine, Houston
C. P. Holstege
Affiliation:
Department of Emergency Medicine, Division of Medical Toxicology, University of Virginia, Charlottesville, United States
R. Farah
Affiliation:
Department of Emergency Medicine, Division of Medical Toxicology, University of Virginia, Charlottesville, United States
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

Kratom (Mitragyna speciosa), a botanical native to Southeast Asia, was traditionally consumed for pain relief and opioid withdrawal. Today, it is marketed as a “natural wellness” product and sold in gas stations, vape shops, and online with minimal oversight. Its shift from whole leaf to high-potency formulations, still labeled as kratom but often enriched with 7-hydroxymitragynine, has raised growing concerns about toxicity.

Objectives

To determine recent changes in kratom use and medically attended kratom-related exposures in the United States (U.S.).

Methods

A retrospective analysis of kratom use and kratom-related exposures was conducted using data from the U.S. National Survey on Drug Use and Health (NSDUH; 2019–2023) and the U.S. National Poison Data System (NPDS; 2015–2024). Analyses included individuals aged 12 years and older in the U.S. and assessed trends in demographics, clinical outcomes, and substances co-used with kratom.

Results

From 2019–2023, NSDUH estimated lifetime kratom use rose from 4.0 to 5.1 million, while past-year (1.6–2.1 million) and past-month use (0.83–1.14 million) remained stable (Figure 1). Males comprised 50–67% of users. NPDS recorded 11,015 medically attended exposures during 2015–2024, increasing from 258 to 1,524 (Figure 2A); 35–43% involved co-use. Most exposures occurred in males (66–76%) and adults aged 20–39, but exposures are rising among older adults (40–59 and >60) and adolescents (Figure 2B). Compared with kratom-only exposures, co-use exposures had nearly double the hospitalization rate (44–56% vs. 24–28%) and more frequent critical care admissions (20–31% vs. 9–12%; Figure 3A). Serious outcomes, including death, were also more common with co-use (56–65%) than kratom alone (42–49%; Figure 3B). Deaths totaled 204, including 169 with co-use. Common co-used substances (ethanol, opioids, benzodiazepines, stimulants, and antidepressants) were also most frequent in hospitalizations and serious outcomes, with opioids predominating in fatalities.Image 1:

A three-panel bar and line graph showing kratom use trends in the U S from 2019 to 2023 across lifetime, past year, and past 30-day categories. See long description.Image 2:

A two-panel figure showing kratom exposure trends from 2015 to 2024 by use type and age group. See long description.Image 3:

Two line graphs showing trends in kratom exposure outcomes from 2015 to 2024. Panel A tracks hospitalization percentages and Panel B tracks serious medical outcomes. See long description.

Conclusions

Kratom use in the U.S. is rising, with medically attended exposures peaking in 2024 alongside the introduction of high-potency formulations enriched with 7-hydroxymitragynine. Hospitalizations and severe outcomes are largely tied to polysubstance use involving psychoactive drugs. These findings highlight the urgent need for enhanced surveillance, regulation of high-potency products, and targeted education to reduce harm in a rapidly evolving drug landscape.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.